INCY
INCYTE CORP
$108.53
+0.65%
$21.7B
No data for this timeframe.
Vol
Market Cap$21.7B
Cap SizeLarge Cap
Analyst ConsensusHold (46%)
Inst. Holders50 funds
Inst. Value$13.6B
Inst. Activity38 buys / 12 sells
Insider Activity0B / 6S
Insider Net $-$7.3M
SEC Reports3
Exchange Nasdaq·Sector Services-Commercial Physical & Biological Research·Inc. DE·CIK 0000879169·Prev Close $107.83
Recent Activity
Jun 12, 2026
clinical_trial_readout
Results Pending: retifanlimab (Phase 2) — Completed 14d ago
Trial: Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapie
Jun 8, 2026
SEC
Incyte announced a definitive agreement to acquire Vega Therapeutics (a Star Therapeutics subsidiary) for $1.25 billion
8-K — Impact 7/10
Jun 8, 2026
Insider
High Katherine A was granted 6,111 shares
Director
Jun 8, 2026
Insider
BRAWLEY OTIS W was granted 6,111 shares
Director
Jun 8, 2026
Insider
BRAWLEY OTIS W was granted 1,642 shares
Director
May 27, 2026
SEC
Incyte filed additional proxy soliciting materials supplementing its definitive proxy statement for the June 8, 2026 ann
DEFA14A — Impact 3/10
Feb 28, 2026
SEC
Three major passive institutional investors — Morgan Stanley, Wells Fargo, and UBS — significantly increased their posit
INST-CLUSTER — Impact 6/10
Inst.
WELLINGTON MANAGEMENT GROUP LLP — DOUBLED
3,266,136 shares ($307.4M)
Price Targets
$109.09
+0.5% upside
Hold
Current $108.53
Low $71.00
Median $105.00
High $140.00
23 analysts
$71.00
$140.00
Analyst Ratings
8Strong Buy
8Buy
18Hold
1Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 9, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| May 22, 2026 | Bernstein | INITIATE | Market Perform |
| May 21, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| May 4, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Apr 29, 2026 | Oppenheimer | MAINTAIN | Perform → Perform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $1.82 ▼ -0.5% | $1.51 — $1.99 | 16% YoY | 19 |
| Next Q | $2.00 ▼ -0.6% | $1.72 — $2.21 | -11% YoY | 16 |
| Current FY | $7.70 | $6.81 — $8.08 | 13% YoY | 20 |
| Next FY | $9.16 ▲ +1.3% | $7.63 — $11.15 | 19% YoY | 19 |
Latest Reports
BULLISH
8-K
7/10
Incyte announced a definitive agreement to acquire Vega Therapeutics (a Star Therapeutics subsidiary) for $1.25 billion
Jun 8, 2026
NEUTRAL
DEFA14A
3/10
Incyte filed additional proxy soliciting materials supplementing its definitive proxy statement for the June 8, 2026 ann
May 27, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BAKER BROS. ADVISORS LP | $2.9B | — |
| BlackRock, Inc. | $1.8B | — |
| DODGE & COX | $1.2B | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $1.0B | — |
| STATE STREET CORP | $907.4M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 8, 2026 | High Katherine | A | $0.00 |
| Jun 8, 2026 | BRAWLEY OTIS | A | $0.00 |
| Jun 8, 2026 | BRAWLEY OTIS | A | $0.00 |
| Jun 8, 2026 | High Katherine | A | $0.00 |
| Jun 8, 2026 | FOUSE JACQUALYN | A | $0.00 |
50 institutional holders with $13.6B total value (144,453,628 shares) as of 2026-Q1. Top holders: BAKER, BlackRock,, DODGE. Net buying activity: 38 institutions added/increased vs 12 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BAKER BROS. ADVISORS LP | 30,744,412 | $2.9B | 21.3% | — |
| 2 | BlackRock, Inc. | 18,978,198 | $1.8B | 13.1% | — |
| 3 | DODGE & COX | 12,252,356 | $1.2B | 8.5% | — |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 10,930,066 | $1.0B | 7.6% | — |
| 5 | STATE STREET CORP | 9,641,384 | $907.4M | 6.7% | — |
| 6 | VANGUARD PORTFOLIO MANAGEMENT LLC | 7,759,183 | $730.3M | 5.4% | — |
| 7 | Invesco Ltd. | 3,870,764 | $364.3M | 2.7% | — |
| 8 | RENAISSANCE TECHNOLOGIES LLC | 3,651,532 | $343.7M | 2.5% | — |
| 9 | WELLINGTON MANAGEMENT GROUP LLP | 3,266,136 | $307.4M | 2.3% | DOUBLED +341.7% |
| 10 | MORGAN STANLEY | 2,850,328 | $268.3M | 2.0% | — |
| 11 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 2,830,799 | $266.4M | 2.0% | — |
| 12 | GOLDMAN SACHS GROUP INC | 2,351,221 | $221.3M | 1.6% | — |
| 13 | LOS ANGELES CAPITAL MANAGEMENT LLC | 2,144,847 | $201.9M | 1.5% | — |
| 14 | DIMENSIONAL FUND ADVISORS LP | 1,975,544 | $185.9M | 1.4% | — |
| 15 | VICTORY CAPITAL MANAGEMENT INC | 1,742,870 | $164.0M | 1.2% | — |
| 16 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,729,102 | $162.7M | 1.2% | — |
| 17 | Legal & General Group Plc | 1,543,188 | $145.2M | 1.1% | — |
| 18 | CAISSE DE DEPOT ET PLACEMENT DU QUEBEC | 1,520,486 | $143.1M | 1.1% | ADD +36.8% |
| 19 | FIRST TRUST ADVISORS LP | 1,500,792 | $141.3M | 1.0% | — |
| 20 | DEUTSCHE BANK AG\ | 1,264,195 | $119.0M | 0.9% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| WELLINGTON MANAGEMENT GROUP LLP | DOUBLED | 739,378 | 3,266,136 | +341.7% | $307.4M | 2026-Q1 |
| CAISSE DE DEPOT ET PLACEMENT DU QUEBEC | ADD | 1,111,193 | 1,520,486 | +36.8% | $143.1M | 2026-Q1 |
| AustralianSuper Pty Ltd | ADD | 640,733 | 1,137,143 | +77.5% | $107.0M | 2026-Q1 |
| Amundi | ADD | 774,186 | 1,003,969 | +29.7% | $94.5M | 2026-Q1 |
| Pictet Asset Management Holding SA | TRIM | 1,315,666 | 916,188 | -30.4% | $84.8M | 2026-Q1 |
| FRANKLIN RESOURCES INC | ADD | 550,096 | 693,785 | +26.1% | $65.3M | 2026-Q1 |
| Gotham Asset Management, LLC | ADD | 352,695 | 676,670 | +91.9% | $63.7M | 2026-Q1 |
| AMERIPRISE FINANCIAL INC | TRIM | 865,150 | 605,474 | -30.0% | $57.0M | 2026-Q1 |
| HSBC HOLDINGS PLC | DOUBLED | 290,255 | 582,368 | +100.6% | $54.8M | 2026-Q1 |
| MACKENZIE FINANCIAL CORP | ADD | 410,362 | 549,633 | +33.9% | $51.7M | 2026-Q1 |
| JUPITER ASSET MANAGEMENT LTD | DOUBLED | 48,581 | 482,642 | +893.5% | $45.4M | 2026-Q1 |
| PRUDENTIAL FINANCIAL INC | ADD | 286,585 | 374,280 | +30.6% | $35.2M | 2026-Q1 |
| CAPITAL FUND MANAGEMENT S.A. | DOUBLED | 136,343 | 312,021 | +128.9% | $29.4M | 2026-Q1 |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | ADD | 212,519 | 297,504 | +40.0% | $28.0M | 2026-Q1 |
| Korea Investment CORP | ADD | 175,726 | 220,926 | +25.7% | $20.8M | 2026-Q1 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | TRIM | 323,124 | 185,081 | -42.7% | $17.4M | 2026-Q1 |
| DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | ADD | 101,810 | 183,834 | +80.6% | $17.3M | 2026-Q1 |
| FJARDE AP-FONDEN /FOURTH SWEDISH NATIONAL PENSION FUND | ADD | 109,219 | 175,469 | +60.7% | $16.5M | 2026-Q1 |
| Point72 Asset Management, L.P. | NEW | — | 168,763 | — | $15.9M | 2026-Q1 |
| Allianz Asset Management GmbH | ADD | 79,205 | 135,105 | +70.6% | $12.7M | 2026-Q1 |
| DANSKE BANK A/S | TRIM | 107,571 | 77,085 | -28.3% | $7.3M | 2026-Q1 |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | ADD | 51,009 | 76,314 | +49.6% | $7.2M | 2026-Q1 |
| ENVESTNET ASSET MANAGEMENT INC | ADD | 40,827 | 64,764 | +58.6% | $6.1M | 2026-Q1 |
| Mediolanum International Funds Ltd | ADD | 48,073 | 60,300 | +25.4% | $5.4M | 2026-Q1 |
| Trexquant Investment LP | ADD | 37,315 | 57,696 | +54.6% | $5.4M | 2026-Q1 |
15 unique insiders with 41 transactions. Net insider value: -$7.3M ($0.00 bought, $7.3M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 8, 2026 | High Katherine A | Director | AWARD | 6,111 | — | — |
| Jun 8, 2026 | BRAWLEY OTIS W | Director | AWARD | 6,111 | — | — |
| Jun 8, 2026 | BRAWLEY OTIS W | Director | AWARD | 1,642 | — | — |
| Jun 8, 2026 | High Katherine A | Director | AWARD | 1,642 | — | — |
| Jun 8, 2026 | FOUSE JACQUALYN A | Director | AWARD | 1,642 | — | — |
| Jun 8, 2026 | FOUSE JACQUALYN A | Director | AWARD | 6,111 | — | — |
| Jun 8, 2026 | BIENAIME JEAN JACQUES | Director | AWARD | 1,642 | — | — |
| Jun 8, 2026 | BIENAIME JEAN JACQUES | Director | AWARD | 6,111 | — | — |
| Jun 8, 2026 | Clancy Paul J | Director | AWARD | 1,642 | — | — |
| Jun 8, 2026 | Clancy Paul J | Director | AWARD | 6,111 | — | — |
| Jun 8, 2026 | HARRIGAN EDMUND | Director | AWARD | 1,642 | — | — |
| Jun 8, 2026 | HARRIGAN EDMUND | Director | AWARD | 6,111 | — | — |
| Jun 4, 2026 | Tray Thomas | Principal Accounting Officer | SELL | 2,639 | $100.00 | $263.9K |
| Jun 4, 2026 | Tray Thomas | Principal Accounting Officer | EXERCISE | 2,639 | $83.83 | $221.2K |
| Jun 1, 2026 | CAGNONI PABLO J | President, Global Head of R&D | TAX W/H | 25,469 | $95.59 | $2.4M |
| May 26, 2026 | BIENAIME JEAN JACQUES | Director | EXERCISE | 15,000 | $84.53 | $1.3M |
| May 26, 2026 | BIENAIME JEAN JACQUES | Director | TAX W/H | 13,059 | $97.10 | $1.3M |
| May 26, 2026 | Tray Thomas | Principal Accounting Officer | SELL | 2,051 | $97.35 | $199.7K |
| May 19, 2026 | Clancy Paul J | Director | SELL | 15,000 | $94.93 | $1.4M |
| May 19, 2026 | Clancy Paul J | Director | EXERCISE | 15,000 | $84.53 | $1.3M |
| May 8, 2026 | BAKER BROS. ADVISORS LP | Director | EXERCISE | 15,000 | $84.53 | $1.3M |
| May 6, 2026 | Stein Steven H | CMO & Head of Late-Stage Dev. | AWARD | 44,124 | — | — |
| May 6, 2026 | CAGNONI PABLO J | President, Global Head of R&D | AWARD | 31,517 | — | — |
| May 4, 2026 | Upadhyay Suketu | EVP & Chief Financial Officer | AWARD | 26,343 | — | — |
| May 4, 2026 | Upadhyay Suketu | EVP & Chief Financial Officer | AWARD | 38,429 | — | — |
| May 4, 2026 | Upadhyay Suketu | EVP & Chief Financial Officer | AWARD | 13,171 | — | — |
| Apr 17, 2026 | CAGNONI PABLO J | President, Global Head of R&D | SELL | 18,667 | $96.50 | $1.8M |
| Apr 17, 2026 | CAGNONI PABLO J | President, Global Head of R&D | EXERCISE | 6,077 | $64.25 | $390.4K |
| Apr 15, 2026 | Stein Steven H | CMO & Head of Late-Stage Dev. | AWARD | 39,049 | — | — |
| Apr 15, 2026 | CAGNONI PABLO J | President, Global Head of R&D | AWARD | 27,892 | — | — |
| Apr 15, 2026 | Meury William | Chief Executive Officer | EXERCISE | 125,000 | — | — |
| Mar 31, 2026 | Clancy Paul J | Director | AWARD | 265 | $94.12 | $24.9K |
| Mar 31, 2026 | BAKER BROS. ADVISORS LP | Director | AWARD | 421 | — | — |
| Mar 31, 2026 | HARRIGAN EDMUND | Director | AWARD | 269 | $94.12 | $25.3K |
| Mar 25, 2026 | Trotta Matteo | EVP, GM, Dermatology US | TAX W/H | 537 | $92.23 | $49.5K |
| Mar 17, 2026 | CAGNONI PABLO J | President, R&D | EXERCISE | 7,166 | $61.18 | $438.4K |
| Mar 17, 2026 | CAGNONI PABLO J | President, R&D | SELL | 18,667 | $94.24 | $1.8M |
| Feb 19, 2026 | CAGNONI PABLO J | President, R&D | EXERCISE | 13,093 | $61.76 | $808.6K |
| Feb 19, 2026 | CAGNONI PABLO J | President, R&D | SELL | 18,668 | $100.91 | $1.9M |
| Feb 2, 2026 | Morrissey Michael James | EVP, Head of Tech. Operations | TAX W/H | 185 | $102.67 | $19.0K |
| Feb 2, 2026 | Heeson Lee | EVP, Head of Incyte Intl | TAX W/H | 111 | $102.67 | $11.4K |
3 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 5.3/10.
BULLISH
8-K
7/10
Incyte announced a definitive agreement to acquire Vega Therapeutics (a Star Therapeutics subsidiary
Jun 8, 2026
NEUTRAL
DEFA14A
3/10
Incyte filed additional proxy soliciting materials supplementing its definitive proxy statement for
May 27, 2026
BULLISH
INST-CLUSTER
6/10
Three major passive institutional investors — Morgan Stanley, Wells Fargo, and UBS — significantly i
Feb 28, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Hold (46% buy). Based on 35 analysts: 8 strong buy, 8 buy, 18 hold, 1 sell, 0 strong sell.
Analyst Price Targets
$109.09 mean target
+0.5% upside
Hold (2.41)
$71.00 Low
$140.00 High
| Metric | Value |
|---|---|
| Current Price | $108.53 |
| Target Low | $71.00 |
| Target Mean | $109.09 |
| Target Median | $105.00 |
| Target High | $140.00 |
| # Analysts | 23 |
| Recommendation | Hold (2.41) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$1.82 | $1.51 | $1.99 | 16.1% | -0.5% | 10↑ 5↓ | $1.4B | 12.5% | 19 |
| Next Q 2026-09-30 |
$2.00 | $1.72 | $2.21 | -11.3% | -0.6% | 5↑ 10↓ | $1.5B | 6.6% | 16 |
| Current FY 2026-12-31 |
$7.70 | $6.81 | $8.08 | 13.2% | -0.3% | 15↑ 4↓ | $5.6B | 9.5% | 20 |
| Next FY 2027-12-31 |
$9.16 | $7.63 | $11.15 | 19.1% | +1.3% | 14↑ 6↓ | $6.3B | 11.4% | 19 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $1.823 | |
| 7d ago | $1.824 | -0.001 |
| 30d ago | $1.833 | -0.009 |
| 60d ago | $1.772 | +0.051 |
| 90d ago | $1.790 | +0.033 |
13 analyst firms have rated this stock: 0 upgrades, 2 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 9, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| May 22, 2026 | Bernstein | INITIATE | — | Market Perform |
| May 21, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 4, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 29, 2026 | Oppenheimer | MAINTAIN | Perform | Perform |
| Apr 29, 2026 | Stifel | MAINTAIN | Buy | Buy |
| Apr 15, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 30, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 25, 2026 | UBS | MAINTAIN | Neutral | Neutral |
| Mar 25, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 16, 2026 | Jefferies | DOWNGRADE | Buy | Hold |
| Mar 9, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 5, 2026 | Evercore ISI Group | MAINTAIN | In-Line | In-Line |
| Feb 18, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Feb 11, 2026 | RBC Capital | MAINTAIN | Sector Perform | Sector Perform |
| Feb 11, 2026 | Stifel | MAINTAIN | Buy | Buy |
| Feb 11, 2026 | Wells Fargo | MAINTAIN | Equal-Weight | Equal-Weight |
| Feb 11, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Feb 6, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Feb 5, 2026 | HC Wainwright & Co. | INITIATE | — | Buy |
| Feb 4, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Jan 20, 2026 | Wells Fargo | DOWNGRADE | Overweight | Equal-Weight |
| Jan 13, 2026 | TD Cowen | MAINTAIN | Buy | Buy |
| Jan 6, 2026 | Morgan Stanley | MAINTAIN | Equal-Weight | Equal-Weight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 8 | 8 | 18 | 1 | 0 | 46% | |
| May 1, 2026 | 8 | 8 | 16 | 1 | 0 | 48% | |
| Apr 1, 2026 | 8 | 8 | 16 | 1 | 0 | 48% | |
| Mar 1, 2026 | 9 | 8 | 15 | 1 | 0 | 52% | |
| Feb 1, 2026 | 9 | 7 | 15 | 1 | 0 | 50% | |
| Jan 1, 2026 | 9 | 8 | 14 | 1 | 0 | 53% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 12, 2026
Clinical Trial
Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.
Phase Phase 2 — COMPLETED
Jun 12, 2026
clinical_trial_readout
Results Pending: retifanlimab (Phase 2) — Completed 14d ago
Trial: Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endo
Jun 12, 2026
short_volume
Short Volume: INCY — 69.8% short (0.4M / 0.6M)
Short: 421,043 | Exempt: 14,930 | TRF Vol: 603,012 | Short Ratio: 69.8% | Off-exchange volume (dark pool + OTC)
Jun 11, 2026
short_volume
Short Volume: INCY — 70.5% short (0.6M / 0.8M)
Short: 581,507 | Exempt: 15,227 | TRF Vol: 825,372 | Short Ratio: 70.5% | Off-exchange volume (dark pool + OTC)
Jun 10, 2026
short_volume
Short Volume: INCY — 75.6% short (0.9M / 1.1M)
Short: 862,819 | Exempt: 20,797 | TRF Vol: 1,140,913 | Short Ratio: 75.6% | Off-exchange volume (dark pool + OTC)
Jun 9, 2026
short_volume
Short Volume: INCY — 66.1% short (0.5M / 0.7M)
Short: 487,054 | Exempt: 1,863 | TRF Vol: 736,682 | Short Ratio: 66.1% | Off-exchange volume (dark pool + OTC)
Jun 5, 2026
short_volume
Short Volume: INCY — 73.1% short (0.8M / 1.1M)
Short: 837,346 | Exempt: 39,868 | TRF Vol: 1,145,931 | Short Ratio: 73.1% | Off-exchange volume (dark pool + OTC)
Jun 4, 2026
Clinical Trial
A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors
Phase Phase 2 — TERMINATED
Jun 4, 2026
short_volume
Short Volume: INCY — 65.9% short (0.4M / 0.7M)
Short: 446,262 | Exempt: 9,374 | TRF Vol: 677,171 | Short Ratio: 65.9% | Off-exchange volume (dark pool + OTC)
Jun 3, 2026
Clinical Trial
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
Phase Phase 3 — ACTIVE_NOT_RECRUITING
Jun 3, 2026
clinical_trial_readout
T-90d Trial Readout: Tafasitamab (Phase 3)
Trial: Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
Sponsor: Incyte Corporation
Jun 3, 2026
short_volume
Short Volume: INCY — 74.4% short (0.7M / 0.9M)
Short: 685,478 | Exempt: 575 | TRF Vol: 921,938 | Short Ratio: 74.4% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
short_volume
Short Volume: INCY — 58.4% short (0.5M / 0.8M)
Short: 470,527 | Exempt: 1,289 | TRF Vol: 805,032 | Short Ratio: 58.4% | Off-exchange volume (dark pool + OTC)
May 31, 2026
Clinical Trial
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
Phase Phase 2 — COMPLETED
May 31, 2026
clinical_trial_readout
Results Pending: Ruxolitinib (Phase 2) — Completed 89d ago
Trial: A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
Sponsor: Incyte Corporation
Phase: Phase 2 | Com
May 25, 2026
dark_pool
Dark Pool: INCY — 1.2M shares, 33,431 trades
Week starting 2026-05-25. Total ATS volume: 1,183,816 shares across 33,431 trades.
May 24, 2026
Clinical Trial
Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms
Phase Phase 2 — TERMINATED
May 18, 2026
dark_pool
Dark Pool: INCY — 1.2M shares, 35,670 trades
Week starting 2026-05-18. Total ATS volume: 1,195,957 shares across 35,670 trades.
May 15, 2026
short_volume
Short Volume: INCY — 73.3% short (0.4M / 0.6M)
Short: 433,808 | Exempt: 858 | TRF Vol: 592,008 | Short Ratio: 73.3% | Off-exchange volume (dark pool + OTC)
May 13, 2026
short_volume
Short Volume: INCY — 78.1% short (0.4M / 0.5M)
Short: 391,439 | Exempt: 68 | TRF Vol: 501,485 | Short Ratio: 78.1% | Off-exchange volume (dark pool + OTC)
May 1, 2026
FDA
JAKAFI XR
Original Approval — Type 5 - New Formulation or New Manufacturer — TABLET
Apr 22, 2024
FDA
ZYNYZ
Supplemental Approval — Labeling — RETIFANLIMAB-DLWR — INJECTABLE — INTRAVENOUS